Back
Amgen Pushes MariTide into Phase 3, Touts 10% Growth
Back
Stock News
Themes
Amgen Pushes MariTide into Phase 3, Touts 10% Growth
CAR-T Therapy
Amgen Pushes MariTide into Phase 3, Touts 10% Growth
Edgen Stock
·
Jan 13 2026, 16:09
Share to
Share to
Copy link
AMGN
+3.81%
source:
[1] Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event
Recommend
Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder Returns
Nov 28 2025, 10:17
US-China AI Rivalry Enters New Phase Focused on Compute Power and Cybersecurity
Nov 28 2025, 10:17
Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder Returns
Nov 28 2025, 10:17